Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919217 · ClinicalTrials.gov registry record
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by University of Louisville.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT00919217 is a study of Relapsing Remitting Multiple Sclerosis that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 80 participants, below the 199-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00919217, a study of Relapsing Remitting Multiple Sclerosis, is actively recruiting participants, sponsored by University of Louisville.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.
Conditions Studied
Study Locations (1)
Kentucky
- University of Louisville (recruiting nationwide) - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-08 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919217
The ClinicalTrials.gov registry entry for NCT00919217 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (60% lower). The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00919217 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT00919217 about?
NCT00919217 is a clinical study titled "Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms". The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.
What is the current status of trial NCT00919217?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2008-08. Estimated completion is 2025-12.
What conditions does trial NCT00919217 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
Who is sponsoring clinical trial NCT00919217?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00919217 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
-
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.